Melinda S Yates Selected Research

1- (2- cyano- 3,12- dioxooleana- 1,9- dien- 28- oyl) imidazole

11/2009	The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice.
10/2009	Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide.
1/2009	Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice.
1/2007	Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes.
2/2006	Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Melinda S Yates Research Topics

Disease

16	Neoplasms (Cancer) 01/2022 - 08/2008
13	Endometrial Neoplasms (Endometrial Cancer) 11/2021 - 08/2013
6	Obesity 01/2021 - 10/2009
5	Body Weight (Weight, Body) 01/2017 - 02/2006
4	Carcinogenesis 06/2009 - 02/2006
4	Inflammation (Inflammations) 06/2009 - 02/2006
3	Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer) 01/2021 - 08/2013
3	Ovarian Neoplasms (Ovarian Cancer) 05/2015 - 09/2009
2	Microsatellite Instability 02/2021 - 08/2017
2	Endometrial Hyperplasia 11/2020 - 01/2017
2	Type 2 Diabetes Mellitus (MODY) 01/2017 - 04/2014
1	Melanoma (Melanoma, Malignant) 01/2022
1	Ovarian Epithelial Carcinoma 02/2021
1	Hyperplasia 01/2021
1	Endometrioid Carcinoma 04/2018
1	Prediabetic State (Prediabetes) 01/2018
1	Colorectal Neoplasms (Colorectal Cancer) 08/2017
1	Hyperinsulinism (Hyperinsulinemia) 07/2013
1	Insulin Resistance 07/2013
1	Critical Illness (Critically Ill) 11/2009
1	Hyperoxia 11/2009
1	Lung Injury 11/2009
1	Acute Lung Injury 11/2009
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2009
1	Chronic Bronchitis 01/2009
1	Emphysema 01/2009
1	Pulmonary Hypertension 01/2009
1	Leukemia 08/2008

Drug/Important Bio-Agent (IBA)

6	Biomarkers (Surrogate Marker)IBA 02/2021 - 08/2013
6	Estrogens (Estrogen)FDA Link 01/2021 - 07/2013
6	Metformin (Glucophage)FDA LinkGeneric 01/2020 - 07/2013
5	1- (2- cyano- 3,12- dioxooleana- 1,9- dien- 28- oyl) imidazoleIBA 11/2009 - 02/2006
5	TriterpenesIBA 11/2009 - 02/2006
3	Everolimus FDA Link 11/2021 - 03/2015
3	Progesterone Receptors (Progesterone Receptor)IBA 01/2021 - 01/2017
3	Proteins (Proteins, Gene)FDA Link 04/2018 - 08/2008
3	Insulin (Novolin)FDA Link 01/2018 - 07/2013
3	bardoxoloneIBA 11/2009 - 01/2009
3	imidazoleIBA 11/2009 - 02/2006
3	EnzymesIBA 11/2009 - 01/2007
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 01/2017
2	Progestins (Progestagens)IBA 11/2020 - 08/2013
2	Letrozole (Femara)FDA LinkGeneric 01/2020 - 03/2015
2	Pharmaceutical PreparationsIBA 01/2017 - 04/2014
2	AflatoxinsIBA 08/2008 - 02/2006
1	PolymersIBA 11/2021
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 02/2021
1	Insulin-Like PeptidesIBA 01/2021
1	Retinal DehydrogenaseIBA 01/2021
1	Levonorgestrel (Plan B)FDA LinkGeneric 01/2021
1	Hormones (Hormone)IBA 01/2021
1	SurvivinIBA 01/2021
1	Estrogen ReceptorsIBA 11/2020
1	DNA Polymerase IIIBA 11/2020
1	Progesterone FDA LinkGeneric 11/2020
1	UbiquitinIBA 01/2020
1	HydrolasesIBA 01/2020
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2020
1	ProteomeIBA 01/2020
1	pevonedistatIBA 01/2020
1	Protein AggregatesIBA 01/2020
1	Granzymes (Granzyme)IBA 08/2017
1	Phosphotransferases (Kinase)IBA 03/2015
1	BiguanidesIBA 12/2013
1	Medroxyprogesterone Acetate (Depo-Provera)FDA LinkGeneric 08/2013
1	Oral ContraceptivesIBA 08/2013
1	DEPOIBA 08/2013
1	Oxygen (Dioxygen)IBA 11/2009
1	Transcription Factors (Transcription Factor)IBA 11/2009
1	AntioxidantsIBA 11/2009
1	LipidsIBA 10/2009
1	NF-E2-Related Factor 2IBA 06/2009
1	SmokeIBA 01/2009
1	TBE 31IBA 08/2008
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 08/2008
1	RNA (Ribonucleic Acid)IBA 01/2007
1	Oleanolic AcidIBA 02/2006
1	DNA AdductsIBA 02/2006

Therapy/Procedure

6	Therapeutics 01/2022 - 12/2013
3	Hysterectomy 11/2021 - 07/2020
3	Salpingo-oophorectomy 07/2020 - 03/2011
3	Chemoprevention 09/2009 - 08/2008
2	Immunotherapy 02/2021 - 08/2017
2	Drug Therapy (Chemotherapy) 01/2020 - 08/2008
1	Intrauterine Devices (Intrauterine Device) 01/2021
1	Salpingectomy 05/2015
1	Oral Administration 11/2009
1	Aftercare (After-Treatment) 01/2009